Anthrax Vaccine: New Developments

Anthrax... So you haven't heard about the vaccine for a while; is the threat of bioterrorism still real?
VaxGen, Inc. a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Emergent BioSolutions paid VaxGen $2 million initially and may be obligated to pay up to an additional $8 million in milestone payments.
VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com/.
While the subject of anthrax may not make daily headline anymore,the companies involved in developing the vaccine are forging ahead. For Officials at CDC, Homeland Security, etc the concern of bioterrorism and the threat of these biological weapons have never wavered.